Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Albiglutide (GSK716155) or exenatide
Albiglutide or exenatide · 1 trial · 1 indication
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline in HbA1c was calculated as the value at Week 16 minus the value at Baseline. Based on ANCOVA: Change = treatment + Baseline HbA1c + prior therapy + gender + region. The last observation carried forward (LOCF) method was used to impute missing data, in which the last valid observation recorded on treatment (scheduled or unscheduled) was used to impute the missing measurement. For participants who had missing observations before their last observation on treatment, the closest previous non-missing on-treatment observation was carried forward to missing visits. If a participant had missing observation(s) immediately after Baseline, the Baseline observation was not carried forward and was left as missing.
| Name | Type | Description |
|---|---|---|
| Albiglutide (GSK716155) or exenatide | DRUG | Albiglutide weekly subcutaneous injection or exenatide twice daily injection |
Inclusion Criteria: * Has type 2 diabetes mellitus as defined by the criteria of the American Diabetes Association and recognized by World Health Organization Expert Committee on the Diagnosis and Classification of Diabetes Mellitus \[American Diabetes Association, 2004a\] at least three months pre...
Albiglutide, also known as GSK716155, and exenatide are GLP-1 receptor agonist drugs developed for type 2 diabetes mellitus. Both are being studied in the metabolic therapeutic area. Albiglutide is being developed by GSK plc under the ticker GSK.
Albiglutide and exenatide are used for the treatment of type 2 diabetes mellitus. They are GLP-1 receptor agonists that help manage blood glucose in adults with this condition.
Albiglutide and exenatide target the GLP-1 receptor, also known as GLP1R. They act as agonists at this receptor, meaning they activate it to stimulate insulin secretion and lower blood glucose in type 2 diabetes.
Albiglutide, also known as GSK716155, is being developed by GSK plc, which trades under the ticker GSK. Exenatide is also included in this development program.
Albiglutide or exenatide is in Phase 2 clinical development for type 2 diabetes mellitus. The program includes one completed Phase 2 trial with 361 participants.
Albiglutide or exenatide has been studied in a Phase 2 trial, NCT00518115, titled Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only. The trial is completed and enrolled 361 participants across the United States, Chile, and the Dominican Republic.